Nuvation Bio Inc.
HealthcareNYSE:NUVB · New York Stock Exchange
+$0.16 today
Vol 5.25M · Avg 4.03M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-66.9%
avg -18.0%
ROIC
-41.0%
avg 54.1%
ROA
-34.4%
avg -106.6%
Analysis
ROA is currently the strongest return metric at -34.4% versus its period average of -106.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David T. Hung | Founder, President, Chief Executive Officer & Chairman | $1.20M | — | 68 | $748,130.00 | 0.22% |
Philippe Sauvage | Chief Financial Officer & Principal Financial Officer | $810,018.00 | — | 48 | $748,130.00 | 0.22% |
Gary Hattersley | Chief Scientific Officer | $805,803.00 | — | 59 | $748,130.00 | 0.22% |
David Liu | Chief Medical Officer | $677,151.00 | — | 56 | $68,000.00 | 0.02% |
Colleen Sjogren | Chief Commercial Officer | $615,841.00 | — | 55 | $748,130.00 | 0.22% |
David C. Hanley | Chief Technical Operations Officer | $586,040.00 | — | 56 | $748,130.00 | 0.22% |
Moses Makunje | Vice President of Finance and Principal Accounting & Financial Officer | — | — | 47 | $224,439.00 | 0.06% |
Kerry A. Wentworth | Chief Regulatory Officer | — | — | 53 | $215,250.00 | 0.06% |
Robert DeVita | Vice President of Corporate Development & Investor Relations | — | — | — | $225,000.00 | 0.06% |
Stacy Markel | Chief People Officer | — | — | 61 | $748,130.00 | 0.22% |
Stephen Dang | Chief Legal Officer & Corporate Secretary | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$1.22M
Sells
12
$7.05M
Net Sentiment
$5.83M
Net selling
Most Active
Liu Dongfang
7 transactions
1–10 of 20
Analysis
Insiders reported 8 buys worth $1.22M and 12 sells worth $7.05M over the last 12 months. That adds up to net selling of $5.83M. Liu Dongfang was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.75B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.47B
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.46B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
$2.03B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$1.96B
uniQure N.V.
NASDAQ:QURE
$1.74B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.60B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
Janux Therapeutics, Inc.
NASDAQ:JANX
$826.95M
Who manages NUVB?
Nuvation Bio Inc. (NUVB) lists 11 active executives. The top listed executive is Colleen Sjogren, Chief Commercial Officer.
Are NUVB insiders buying or selling?
Recent insider activity shows net buying of $97.56M.
Explore More
Continue the stock analysis
Jump to another research area for this company.